Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 269

The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.

Serum S100β: A noninvasive marker of blood‐brain barrier function and brain lesions

Open access
Kanner, Andrew A., Marchi, Nicola, Fazio, Vincent, Mayberg, Marc R., Koltz, Michael T., Siomin, Vitaly, Stevens, Glen H. J., Masaryk, Thomas, Ayumar, Barbara, Vogelbaum, Michael A., Barnett, Gene H., Janigro, Damir · 2003 · Cancer

Abstract

BACKGROUND: S100β protein is expressed constitutively by brain astrocytes. Elevated S100β levels in cerebrospinal fluid and serum reported after head trauma, subarachnoid hemorrhage, and stroke were correlated with the extent of brain damage. Because elevated serum S100β also was shown to indicate blood‐brain barrier (BBB) dysfunction in the absence of apparent brain injury, it remains unclear whether elevation of serum levels of S100β reflect BBB dysfunction, parenchymal damage, or both. METHODS: The authors conducted a prospective study of serum S100β levels in six patients who underwent hyperosmotic BBB disruption (BBBD) with intraarterial chemotherapy for primary central nervous system lymphoma. In addition, 53 serum S100β samples were measured in 51 patients who had a variety of primary or metastatic brain lesions at the time of neuroimaging. RESULTS: S100β was correlated directly with the degree of clinical and radiologic signs of BBBD in patients who were enrolled in the hyperosmotic study. In patients with neoplastic brain lesions, gadolinium enhancement on a magnetic resonance image was correlated with elevated S100β levels (n = 45 patients; 0.16 ± 0.1 μg/L; mean ± standard error of the mean) versus nonenhancing scans (n = 8 patients; 0.069 ± 0.04 μg/L). Primary brain tumors (n = 8 patients; 0.12 ± 0.08) or central nervous system metastases also presented with elevated serum S100β levels (n = 27 patients; 0.14 ± 0.34). Tumor volume was correlated with serum S100β levels only in patients with vestibular schwannoma (n = 6 patients; 0.13 ± 0.10 μg/L) but not in patients with other brain lesions. CONCLUSIONS: S100β was correlated directly with the extent and temporal sequence of hyperosmotic BBBD, further suggesting that S100β is a marker of BBB function. Elevated S100β levels may indicate the presence of radiologically detectable BBB leakage. Larger prospective studies may better determine the true specificity of S100β as a marker for BBB function and as an early detection or follow‐up marker of brain tumors. Cancer 2003;97:2806–13. © 2003 American Cancer Society. DOI 10.1002/cncr.11409

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/cncr.11409

Cites

26 of 26 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 26 references

Cited by

See all 269

Metadata

Authors
Kanner, A. A., Marchi, N., Fazio, V., Mayberg, M. R., Koltz, M. T., Siomin, V., Stevens, G. H. J., Masaryk, T., Ayumar, B., Vogelbaum, M. A., Barnett, G. H., & Janigro, D.
Venue
Cancer
Publisher
Wiley
Published
2003-05-19
Volume
97
Issue
11
Pages
2806-2813
ISSN
  • 0008-543X (ISSN-L)
  • 1097-0142
OpenAlex
W2049278300
Cited by
269
References
26
FWCI
2.47
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Serum S100β: A noninvasive marker of blood‐brain barrier function and brain lesions. https://app.cochat.ai/papers/10.1002/cncr.11409
The paper
Kanner, A. A., Marchi, N., Fazio, V., Mayberg, M. R., Koltz, M. T., Siomin, V., Stevens, G. H. J., Masaryk, T., Ayumar, B., Vogelbaum, M. A., Barnett, G. H., & Janigro, D. (2003). Serum S100β: A noninvasive marker of blood‐brain barrier function and brain lesions. Cancer. https://doi.org/10.1002/cncr.11409

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.